VALBIOTIS: management transactions · France · AMF

About VALBIOTIS

Valbiotis is a French health company focused on the development and commercialization of scientifically tested dietary supplements designed to support health throughout life. Listed on Euronext Growth Paris under the ticker ALVAL and ISIN FR0013254851, the company was founded in La Rochelle in 2014 by Sébastien Peltier and co-founders. Its original business model was built around research in nutritional health and metabolic prevention. After joining Euronext Growth in 2017, Valbiotis spent several years building a proprietary R&D platform before pivoting toward a more commercial model in 2024-2025. Today, the company’s business is organized around two main product families: Valbiotis PRO® and Valbiotis PLUS®. The Valbiotis PRO® range is supported by ten years of research and proprietary clinical studies, with a focus on scientifically backed solutions for cardio-metabolic health concerns such as metabolism, glucose control, lipids, blood pressure, and weight management. The Valbiotis PLUS® range addresses key peripheral factors involved in cardio-metabolic balance and relies on ingredients whose efficacy and safety are widely supported by scientific literature. In 2025, Valbiotis expanded its portfolio and accelerated its commercial rollout, particularly through pharmacies, while increasing brand visibility among healthcare professionals and consumers. From a market standpoint, Valbiotis occupies a niche position within the scientifically oriented dietary supplement segment, sitting between mass-market consumer wellness brands and more specialized health-oriented offerings. Its differentiation comes from clinical credibility, the quality of its formulations, and a preventive-health narrative anchored in science. The company reached an important milestone in 2024 with its first market launches, confirming its transition from a pure R&D story into a revenue-generating commercial health business. Geographically, France remains Valbiotis’ core market and operational anchor. That said, the company has already begun international expansion, signing major partnerships in Asia and later in the Middle East, which indicates a targeted growth strategy beyond its domestic base. Recent notable events include a capital increase in June 2025 to support commercial expansion and, in autumn 2025, a reaffirmed roadmap extending through 2030. Valbiotis is also recognized as an innovative company and is part of Bpifrance’s Excellence network, reinforcing its profile as a science-driven health company with growth ambitions.